

NOV 03 2005

WOOD, HERRON & EVANS, L.L.P.

BRUCE TITTEL
DONALD F. FREI
DAVID S. STALLARD
J. ROBERT CHAMBERS
GREGORY J. LUNN
KURT L. GROSSMAN
CLEMENT H. LUKEN, JR.
THOMAS J. BURGER
GREGORY F. AHRENS
WAYNE L. JACOBS
KURT A. SUMME
KEVIN G. ROONEY
KEITH R. HAUPT
THEODORE R. REMAKLUS
THOMAS W. HUMPHREY
SCOTT A. STINEBRUNER
DAVID H. BRINKMAN
BEVERLY A. LYMAN, PH.D.
KRISTI L. DAVIDSON

OF COUNSEL
JOHN D. POFFENBERGER
DAVID J. JOSEPHIC
THOMAS W. FLYNN
J. DWIGHT POFFENBERGER, JR.
BRADLEY D. BECK

2700 CAREW TOWER
441 VINE STREET
CINCINNATI, OHIO 45202-2917
TELEPHONE: 513-241-2324
FACSIMILE: 513-241-6234
WEBSITE: www.whepatent.com
PATENT, TRADEMARK, COPYRIGHT
AND UNFAIR COMPETITION LAW
AND RELATED LITIGATION

EDMUND P. WOOD 1923-1968
TRUMAN A. HERRON 1935-1976
EDWARD B. EVANS 1936-1971

November 3, 2005

JOSEPH R. JORDAN
C. RICHARD EBY
KATHRYN E. SMITH
P. ANDREW BLATT, PH.D.
DAVID E. JEFFERIES
WILLIAM R. ALLEN, PH.D.
JOHN PAUL DAVIS
DOUGLAS A. SCHOLER
BRETT A. SCHATZ
DAVID W. DORTON
SARAH OTTE GRABER
STEVEN W. BENINTENDI, PH.D.
RANDALL S. JACKSON, JR.
TECHNICAL ADVISORS
HENRY M. LABODA, PH.D.

FACSIMILE COVER SHEET

To: Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Fax: 571-273-8300

From: David E. Jefferies

Re: Response to Office Action and Amendment
Application Serial No. 10/047,578
Filed October 26, 2001
PHENYLEPHRINE TANNATE AND
PYRILAMINE TANNATE SALTS IN
PHARMACEUTICAL COMPOSITIONS
Jeffrey S. Kiel, et al.
Our File: PEDI-04 (formerly KIEL-02)

Pages: ⁴/₃₇ (including cover sheet)**MESSAGE/COMMENTS**

The information in this facsimile message is ATTORNEY-CLIENT PRIVILEGED, WORK PRODUCT and/or CONFIDENTIAL INFORMATION intended only for the use of the individual or entity to whom this message is addressed. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or reproduction of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone and return the original message to us at the above address via mail. Thank you. If transmission is interrupted or of poor quality, please notify us immediately by calling (513) 241-2324 and ask for the sender's assistant. OUR FAX NUMBER IS (513) 241-6234.

Application Serial No. 10/047,578
Declaration under 37 CFR § 1.1.32
Reply to Office Action dated May 4, 2005

Failure to do so may result in a subpotent and unmarketable product. The necessity of performing such a calculation decreases the efficiency of the manufacturing process and introduces another possible source of error, which could still result in content variability greater than the claimed composition of the '578 patent.

12) The general cause of increased content variability that is inherently produced in Chopdekar and Gordziel is not difficult to explain. Each step or operation performed in a manufacturing environment introduces some level of variability into the finished product. When the operation in question, such as a method of Chopdekar and Gordziel, involves isolating a tannate salt, such as by beginning with the free-base form and then converting to the tannate salt, and thereafter processing those tannate salts into a composition, the variability is focused on the amount of active ingredient contained in the finished pharmaceutical product. By eliminating the additional isolation step required by the prior art that is a potential source of increased content variability, the compositions as presently claimed are able to provide a consistently better finished product. Thus, by starting with a commonly available salt or free base of the active pharmaceutical ingredient, which is subsequently converted and incorporated in situ as a tannate salt complex, the invention provides an efficient and reproducible method to manufacture liquid or semi-solid products containing tannate salt complexes as active ingredients.

Application Serial No. 10/047,578
Declaration under 37 CFR § 1.1.32
Reply to Office Action dated May 4, 2005

13) The decreased content variability that results in the claimed compositions due to the recited method has many real world advantages. A better-finished product in the pharmaceutical industry means a safer drug. The principal properties affected by converting a drug to the tannate salt form is solubility, which normally decreases after conversion to a tannate from a hydrochloride salt or bromide salt. The decreased solubility attained in this matter gives the drug prolonged action characteristics. Changes in the content of the tannate salt in a final drug product can potentially alter the overall amount of drug taken, as well as the rate at which the drug enters the body. Understandably, then, increased variability in drug content leads to increased risk to the patient taking the drug product. The need for increased safety and content uniformity is multiplied by the fact that many of the tannate drug products are designed for use by children.

14) I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Application Serial No. 10/047,578
Declaration under 37 CFR § 1.1.32
Reply to Office Action dated May 4, 2005

Further Declarant sayeth naught.

10/24/05
Date

H. Greg Thomas
H. Greg Thomas